10-Q: ETHZilla Pivots to Ethereum, Reports Q3 Loss Amid Capital Influx
Quarterly Report
ETHZilla Corporation has shifted its core business to an Ethereum-focused treasury strategy, reporting a significant net loss in Q3 2025 despite substantial capital raises and the alleviation of going concern doubts.
Summary
- The company has made a strategic pivot, discontinuing its pharmaceutical research operations and Gaming Technology Platform to focus entirely on an Ethereum (ETH)-focused treasury management strategy, including staking and decentralized finance (DeFi) activities.
- For the nine months ended September 30, 2025, revenue from continuing operations was $4,110,169, compared to $0 in the prior year.
- General and administrative expenses surged to $227,954,479 for the nine months ended September 30, 2025, a significant increase from $3,471,965 in the prior year, primarily driven by approximately $209 million in non-cash stock compensation related to options and warrants.
- The net loss from continuing operations for the nine months ended September 30, 2025, was $(212,008,038), compared to a net loss of $(1,658,746) in the prior year.
- The total net loss for the nine months ended September 30, 2025, was $(220,837,892), compared to $(1,894,683) in the prior year, including a net loss from discontinued operations of $(8,829,854).
- Cash and cash equivalents increased to $53,309,509 as of September 30, 2025, from $4,567,251 at December 31, 2024.
- Restricted cash equivalents totaled $505,591,875 as of September 30, 2025, up from $0 at December 31, 2024, primarily due to collateral for convertible debt.
- Digital assets held amounted to $180,933,721 and staking receivables were $257,604,249 as of September 30, 2025.
- The company successfully raised significant capital, including $500 million from convertible debt and $286.8 million from shares issued for cash and warrants, which alleviated prior substantial doubt about its ability to continue as a going concern.
- An investment of $15 million (cash and stock) was made to acquire a 15% interest in Satschel, Inc., which owns Liquidity.io, a regulated broker-dealer and Digital Alternative Trading System (ATS) platform, securing exclusive rights to list Ethereum Layer 2 tokens.
- A stock repurchase program of up to $250 million was authorized, with $16,121,428 of common stock repurchased by September 30, 2025, and an additional $30,141,810 repurchased subsequent to the quarter end.
Sentiment
Score: 4
Explanation: While the company has successfully raised significant capital and pivoted to a high-growth, innovative industry (DeFi/Ethereum), the substantial net loss, high G&A expenses driven by stock compensation, and the inherent volatility and regulatory risks of digital assets temper the positive outlook. The strategic shift is ambitious but unproven over the long term, and the financial performance for the period is significantly negative.
Positives
- Substantial doubt about the company's ability to continue as a going concern has been alleviated due to significant fundraising events.
- Successfully raised over $825 million in financing activities, including $500 million from convertible debt and $286.8 million from shares issued for cash and warrants.
- Implemented a new Ethereum-focused treasury management strategy, with over 70% of the ETH treasury deployed in staking, lending, and DeFi protocols to generate yields.
- Acquired a 15% interest in Satschel, Inc. (Liquidity.io), a regulated Digital ATS platform, gaining exclusive rights to list Ethereum Layer 2 tokens, establishing a foundation for future growth in tokenized real-world assets.
- Initiated a $250 million stock repurchase program, demonstrating confidence in the company's valuation and commitment to returning capital to shareholders.
- Recognized $7,549,815 in digital asset gains and losses and a $3,724,344 gain from changes in the fair value of convertible debt for the nine months ended September 30, 2025.
Negatives
- Reported a significant net loss of $(220,837,892) for the nine months ended September 30, 2025, a substantial increase from $(1,894,683) in the prior year.
- General and administrative expenses increased dramatically to $227,954,479 for the nine months ended September 30, 2025, primarily due to $209 million in non-cash stock compensation.
- Discontinued pharmaceutical research operations and the Gaming Technology Platform, resulting in an impairment loss of $7,622,041 on the Gaming Technology Platform intangible assets.
- Experienced a net loss from discontinued operations of $(8,829,854) for the nine months ended September 30, 2025.
- The company's common stock has experienced high volatility, trading as high as $174.60 and as low as $6.58 (post-split adjusted) in the last 52 weeks.
Risks
- The Transaction Agreement is collateralized by approximately $125 million of ETH, and an event of default could lead to the counterparty taking ownership of the ETH.
- Stockholders may experience significant dilution from the conversion of approximately $516 million in outstanding convertible notes, which include anti-dilution provisions and conversion price resets.
- Convertible notes contain covenants that limit the company's flexibility, including restrictions on issuing additional securities or maintaining a loan-to-value ratio.
- The convertible notes are secured by $656.25 million in cash and $94.5 million of ETH; a default could enable the investor to take ownership of these assets.
- The investor has the right to require redemption of the convertible notes after May 8, 2026, or if the loan-to-value ratio exceeds 85%, potentially forcing the company to sell equity or borrow funds.
- The company will need to raise additional funding to repay the $50 million owed under the Transaction Agreement by December 8, 2025, and $516 million in Convertible Notes by September 23, 2028.
- ETH is a highly volatile asset, and fluctuations in its price are likely to influence the company's financial results and the market price of its common stock.
- The ETH strategy has not been tested over an extended period or under different market conditions, and its success depends significantly on the ability to continue raising capital to purchase ETH.
- Staking ETH introduces 'slashing risks,' which are punitive mechanisms that could result in the loss of staked ETH due to validator misbehavior or inactivity.
- Staked ETH tokens will be inaccessible for a variable period, determined by network conditions and agreements, which could result in liquidity risk.
- The company is dependent on third parties (custodians, staking providers) to effectively execute its staking activities, exposing it to risks of service outages or suboptimal performance.
- Liquid staking applications, such as Lido, may pose risks associated with concentration of control if a single entity manages a significant portion of staked ETH.
- ETH and other digital assets are subject to significant legal, commercial, regulatory, and technical uncertainty, including potential classification as a 'security' or 'commodity,' which could lead to increased oversight and compliance costs.
- The shift towards an ETH-focused strategy requires substantial changes in day-to-day operations and exposes the company to significant operational risks related to validator nodes, key management, uptime, and cybersecurity.
- The company faces risks relating to the custody of its ETH, including the loss or destruction of private keys, cyberattacks, and the potential for custodially-held ETH to become part of a custodian's insolvency estate.
- The use of smart contracts or decentralized applications in staking and DeFi activities entails risks from coding flaws or 'admin key' misuse, potentially leading to the irreversible loss of ETH.
- The market price of ETH is highly volatile and may be adversely affected by factors beyond the company's control, including competition from other crypto assets and relative-adoption trends.
- The further development and acceptance of cryptocurrency networks, including the ETH network, are subject to a variety of factors that are difficult to evaluate, and a decline in popularity could harm the stock price.
- The unregulated nature and lack of transparency of many digital asset trading venues may lead to greater fraud, security failures, or operational problems, adversely affecting digital asset values.
- The company's common stock may trade at a substantial premium or discount to the value of the ETH held and may be more volatile than the price of ETH.
- The availability of spot Exchange Traded Products (ETPs) for ETH and other digital assets may adversely affect the market price of ETH and, consequently, the trading price of the common stock.
- The value of ETH may be subject to momentum pricing due to speculation, leading to greater volatility.
- The launch of central bank digital currencies (CBDCs) may adversely impact the company's business by reducing demand for private-sector cryptocurrencies.
- Intellectual property disputes related to the open-source structure of digital asset networks expose the company to risks related to software development, security vulnerabilities, and potential disruptions.
- The irreversibility of digital asset transactions exposes the company to risks of theft, loss, and human error.
- The company faces significant competition in the growing digital asset industry.
- The emergence or growth of other digital assets, including stablecoins or CBDCs, could have a negative impact on the price of ETH.
- Changes in the accounting treatment of ETH holdings (e.g., ASU 2023-08) could have significant accounting impacts, including increasing the volatility of financial results.
- The concentration of ETH holdings limits the company's ability to mitigate risk through diversification.
- ETH holdings are less liquid than cash and cash equivalents and may not serve as a source of liquidity to the same extent.
- A 'fork' in the Ethereum protocol could adversely affect the value of ETH holdings.
- A disruption of the Internet may affect the operation of cryptocurrency networks.
- Lending arrangements may expose the company to risks of borrower default, operational failures, and cybersecurity threats.
- The ETH strategy exposes the company to risk of non-performance by providers and counterparties, particularly custodians.
- Resales of common stock by stockholders, or the perception of such sales, may cause the market price to fall.
- Holders of convertible securities may engage in hedging or short-selling activities, putting downward pressure on the stock price.
- The company currently has an illiquid and volatile market for its common stock.
- Stock repurchases are discretionary and may not achieve desired objectives.
- Sales of common stock through the ATM Sales Agreement, or the perception of such sales, could cause the market price to fall.
- Future dilution may occur from conversion of convertible notes or future equity/debt offerings.
- Acquisitions may disrupt or negatively impact the business.
- Failure to expand ETH staking operations and/or commercialize plans to securitize real-world assets (RWA) could result in the company being deemed a shell company again.
- Regulatory uncertainties related to the tokenization and securitization of real-world assets may adversely affect the business and could result in significant compliance costs, enforcement actions, or limitations on operations.
Future Outlook
The company intends for staking to become a primary yield generation strategy within the current fiscal year. It plans to raise additional capital to increase its ETH position in an accretive manner and deploy the majority of its ETH treasury across staking, lending, and advanced DeFi protocols to generate yields. ETH is expected to serve as the primary treasury reserve asset, with the goal of maximizing ETH accumulation and value accretion. The company also plans to offer tokenization solutions, DeFi protocol integration, blockchain analytics, and traditional-to-digital asset conversion gateways in the future.
Management Comments
- Our goal is to acquire and grow our overall ETH position and utilize professional treasury strategies to significantly increase our ETH holdings.
- We believe Ethereums unparalleled programmability, security and developer momentum will make it a foundational layer for the next generation of decentralized financial applications.
- We believe that ETHs value proposition at its core is a digital trust commodity and that an investment in ETH represents an asymmetric long-term growth opportunity as more stablecoins and other tokenized real-world assets are secured by the Ethereum ecosystem.
- Our treasury is designed with the goal of bringing value to our stockholders in a variety of ways.
- We plan to continue to deploy the majority of the ETH in our treasury across staking, lending, and advanced DeFi protocols to generate yields and turn the treasury into a productive asset.
- We do not hedge our ETH and do not currently have plans to hedge our ETH in the future.
- Our participation is expected to yield economic return while also contributing directly to Ethereums decentralization, scalability, and security.
- We believe staking is foundational to a new generation of blockchain-native capital structures that enable corporations to earn yield without relying on traditional debt instruments, equities, or centralized intermediaries.
- Our staking efforts are focused on maximizing yield, managing risk and ensuring that the Companys operations meet institutional standards for transparency and efficiency.
- We believe this relationship with Satschel establishes a foundation for our anticipated future growth and delivers several key strategic benefits.
Industry Context
ETHZilla's strategic pivot to an Ethereum-focused treasury management and DeFi strategy positions it within a rapidly evolving segment of the financial industry. This move aligns with the broader trend of institutional adoption of digital assets and the increasing interest in yield-generating activities within the decentralized finance ecosystem. The acquisition of a stake in Liquidity.io, a regulated Digital ATS platform, further integrates the company into the emerging market for tokenized real-world assets (RWAs), a key area of innovation where blockchain technology is being applied to traditional financial instruments. This strategy reflects a shift from traditional biotechnology and iGaming ventures towards leveraging the programmable nature of Ethereum for financial services.
Comparison to Industry Standards
- The company's strategy to accumulate ETH and deploy it in staking, lending, and DeFi protocols is comparable to other institutional players and crypto-native companies seeking to generate yield from digital assets.
- The average annual percentage yield for ETH staking, generally ranging from approximately 2% to 5% as mentioned in the filing, is consistent with general industry benchmarks for Ethereum staking rewards.
- The acquisition of a 15% interest in Satschel, Inc. (Liquidity.io), a regulated broker-dealer and Digital ATS platform, positions ETHZilla in the nascent but growing market for tokenized real-world assets, a space where traditional financial institutions are also exploring blockchain integration.
- The company's use of multiple third-party qualified custodians (e.g., Coinbase) and adherence to SOC type 2 reports for digital asset custody aligns with best practices for institutional-grade digital asset management, aiming to mitigate risks associated with holding significant digital assets.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Dr. James N. Woody | Blair Jordan | 2024-05-07 | Resignation of Dr. Woody. |
| Chief Accounting Officer | Blair Jordan (Principal Accounting/Financial Officer) | Eric R. Van Lent | 2025-02-15 | Appointment of Eric R. Van Lent. |
| Chief Executive Officer | Blair Jordan | McAndrew Rudisill | 2025-09-15 | Blair Jordan entered into a Separation and Release Agreement. |
| Director | Stephen H. Shoemaker | NA | 2025-09-15 | Resignation from the Board of Directors. |
| Chief Financial Officer | NA | John Saunders | 2025-11-15 | Appointment. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorized Shares Increase | Increased authorized common stock from 100 million to 1 billion shares on July 24, 2025, and further to 5 billion shares on October 8, 2025. | 2025-07-24 | Facilitates future capital raises and equity compensation, but increases potential for dilution of existing shareholders. |
| Name Change | Changed company name from 180 Life Sciences Corp. to ETHZilla Corporation. | 2025-08-18 | Reflects the company's strategic pivot to an Ethereum-focused business model. |
| Reverse Stock Split | Effected a 1-for-10 reverse stock split. | 2025-10-20 | Reduced the number of outstanding shares, increased the per-share price, and proportionately adjusted equity awards and warrants. Fractional shares were repurchased for cash. |
| Stock Incentive Plan Adoption | Adopted the 2025 Option Incentive Plan and 2025 Supplemental Option Incentive Plan, reserving shares for awards. | 2025-06-17 | Provides a framework for equity compensation to attract and retain talent, subject to stockholder approval and Nasdaq rules. |
| Stock Repurchase Program | Authorized a stock repurchase program for up to $250 million of common stock. | 2025-08-22 | Aims to enhance shareholder value and manage share count, subject to market conditions and management discretion. |
| Non-Executive Director Compensation Increase | Increased yearly compensation for non-employee directors from $350,000 to $450,000. | 2025-11-12 | Aims to attract and retain qualified independent directors, increasing general and administrative expenses. |
| CEO Salary Increase | Increased CEO McAndrew Rudisill's annual salary from $450,000 to $650,000. | 2025-11-12 | Reflects increased responsibilities and performance expectations, increasing general and administrative expenses. |
| Internal Control Weakness | Identified a material weakness in internal control over financial reporting due to limited accounting resources. | 2025-09-30 | Requires remediation efforts to ensure timely prevention or detection of material misstatements in financial statements. |
Legal Proceedings
- Settled a declaratory relief action with AmTrust International Underwriters DAC and AmTrust Financial Services, Inc. for a cash payment of $250,000 and the issuance of 50,971 shares of common stock (fair value $441,406).
- Settled disputes with Elray Resources, Inc. and Luxor Capital, LLC, acquiring 131,800 shares of common stock from Elray for an aggregate settlement payment of $1 million (consisting of $350,000 cash to Elray and $650,000 to Luxor payable from future capital raises).
Related Party Transactions
- Accounts payable related parties totaled $20,246 as of September 30, 2025, consisting of amounts due to certain officers and directors, as well as deferred compensation.
- Research and Development Expenses Related Parties amounted to $416,870 for the nine months ended September 30, 2025, related to consulting and professional fees paid to current or former officers, directors, or greater than 10% investors, or affiliates thereof, included in net loss from discontinued operations.
- The Elray Settlement Agreement involved Elray Resources, Inc. and Luxor Capital, LLC, both controlled by Anthony Brian Goodman, the father of the company's then-director, Jay Goodman.
- Subsequent Strategic Advisor Warrants to purchase 95,700 shares of common stock were granted to PCAO, of which Mr. McAndrew Rudisill, the current Chief Executive Officer, is the founder and managing partner.
Stakeholder Impact
- Shareholders face significant dilution risk from the conversion of outstanding convertible notes and potential future equity offerings, but may benefit from the stock repurchase program and potential appreciation of ETH holdings.
- Employees and management benefit from increased salaries, equity awards, and incentive plans, reflecting the company's commitment to attracting and retaining talent in its new strategic direction.
- Creditors, particularly convertible noteholders, are in a senior secured position with significant ETH and cash collateral, which mitigates their risk.
- Customers and partners in the DeFi and RWA tokenization space could see new opportunities and services as the company leverages its investment in Liquidity.io and its Ethereum-focused strategy.
Next Steps
- Continue to acquire and grow the overall ETH position and utilize professional treasury strategies to significantly increase ETH holdings.
- Deploy the majority of the ETH treasury across staking, lending, and advanced DeFi protocols to generate yields.
- Offer tokenization solutions, DeFi protocol integration, blockchain analytics, traditional-to-digital asset conversion gateways, and other DeFi services in the future.
- Seek stockholder approval for the issuance of shares of common stock upon conversion of the September 2025 Convertible Notes.
- Negotiate a separate or amended asset management agreement for investments in securities or commodities, provided the Asset Manager obtains requisite regulatory licenses and approvals.
- Continue the stock repurchase program up to $250 million until June 30, 2026, or until the maximum amount is repurchased.
- Repay $51,326,284 for the collateralized loan by December 8, 2025.
- Repay $516 million in Convertible Notes by September 23, 2028.
- Oxford University Innovation Limited will endeavor to negotiate and finalize the sale of the OUI Patent and Company IP, with the company receiving 50% of remaining net revenues (up to $5 million) if acquired within 36 months.
- Evaluate the potential impact of new accounting guidance (ASU 2024-04, ASU 2024-03, ASU 2025-01, ASU 2023-09) on disclosures and financial statements.
- Remediate the identified material weakness in internal controls over financial reporting by implementing an added layer of technical review for significant entries.
Key Dates
| Date | Description |
|---|---|
| 2016-09-07 | Company organized as a blank check company (KBL Merger Corp. IV). |
| 2018-03-07 | Katexco Pharmaceuticals Corp. incorporated. |
| 2018-03-08 | CannBioRex Pharmaceuticals Corp. (CBR Pharma) incorporated. |
| 2018-05-13 | Research and License Agreement dated between the Company and Yissum. |
| 2019-01-28 | 180 Life Corp. incorporated. |
| 2019-05-31 | Katexco Callco, ULC, Katexco Purchaseco, ULC, CannBioRex Callco, ULC, and CannBioRex Purchaseco, ULC formed. |
| 2021-02-19 | Securities Purchase Agreement entered into with investors. |
| 2021-07-01 | Assets and liabilities of Canadian companies (Katexco and CBR Pharma) transferred to U.S. and U.K. subsidiaries. |
| 2021-08-19 | Securities Purchase Agreement entered into with investors. |
| 2022-06-29 | AmTrust International Underwriters DAC filed a declaratory relief action against the Company. |
| 2022-09-01 | Ethereum transitioned from Proof-of-Work to Proof-of-Stake (Merge). |
| 2023-12-01 | Warrant inducement transaction occurred. |
| 2024-01-01 | Company adopted ASU No. 2023-07, Segment Reporting. |
| 2024-02-16 | Stockholders approved an amendment to effect a reverse stock split (ratio between one-for-four to one-for-forty). |
| 2024-02-16 | Board approved a 1-for-19 reverse stock split. |
| 2024-02-28 | The 1-for-19 reverse stock split became effective, and shares began trading on Nasdaq on a post-split basis. |
| 2024-05-07 | Dr. James N. Woody resigned as Chief Executive Officer and director, and entered into a Separation and Release Agreement. |
| 2024-09-29 | Company entered into an Asset Purchase Agreement with Elray Resources, Inc. for blockchain casino technology. |
| 2024-09-30 | Purchase of Purchased Assets from Elray Resources, Inc. closed; 1,000,000 shares of Series B Convertible Preferred Stock issued to Elray. |
| 2024-10-16 | Company entered into a warrant inducement agreement with a holder to exercise warrants for 95,007 shares of common stock. |
| 2024-10-16 | Exercised Warrants were exercised in full for cash. |
| 2024-10-24 | Board determined that members of the Strategy and Alternatives, Risk, Safety and Regulatory Committee would not receive additional compensation. |
| 2024-11-01 | Biotechnology related to 7nAChR was returned to Stanford University. |
| 2024-11-01 | FASB issued ASU 2024-04 (Debt Debt with Conversions and Other Options) and ASU 2024-03 (Income Statement Reporting Comprehensive Income Expense Disaggregation Disclosures). |
| 2024-12-27 | Company entered into a Securities Purchase Agreement with accredited investors for 120,000 common shares and warrants. |
| 2024-12-27 | The Conversion Rate of the Series B Convertible Preferred Stock was fixed at 0.1318 (131,800 total shares of common stock). |
| 2024-12-30 | The December 2024 offerings closed. |
| 2025-01-01 | Company adopted ASU No. 2023-07. |
| 2025-01-01 | FASB issued ASU 2025-01 (Clarifying the Effective Date for ASU 2024-03). |
| 2025-01-30 | Company cancelled 239 shares previously issued to Tyche Capital LLC. |
| 2025-02-04 | Ryan Smith appointed Lead Independent Director. |
| 2025-02-05 | Company entered into a First Amendment to Separation and Release Agreement with Dr. Woody. |
| 2025-02-05 | Dr. Woody entered into a Voting Agreement with the Company. |
| 2025-02-15 | Eric R. Van Lent appointed Chief Accounting Officer; Blair Jordan stepped down from this role. |
| 2025-02-15 | Company entered into an Executive Consulting Agreement with Mr. Van Lent and EVL Consulting, LLC. |
| 2025-02-20 | Company entered into an Executive Consulting Agreement with Mr. Blair Jordan and Blair Jordan Strategy and Finance Consulting Inc. |
| 2025-03-07 | Compensation Committee and Board approved the grant of 6,500 restricted common shares to non-executive directors and 3,000 to an attorney. |
| 2025-03-27 | Elray Resources, Inc. converted all 1,000,000 outstanding shares of Series B Convertible Preferred Stock into 131,800 shares of common stock. |
| 2025-03-31 | Company's annual report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC. |
| 2025-04-06 | Company entered into a Confidential Settlement Agreement and Release with AmTrust International Underwriters DAC and AmTrust Financial Services, Inc. |
| 2025-04-25 | Amendment No. 1 to Annual Report on Form 10-K filed. |
| 2025-04-28 | Company entered into a Settlement and Mutual Release Agreement with Elray and Luxor Capital, LLC. |
| 2025-04-28 | Elray agreed to enter into a Voting Agreement with the Company. |
| 2025-04-30 | Joint stipulation of dismissal with prejudice of the Coverage Action granted. |
| 2025-05-08 | Amendment No. 2 to Annual Report on Form 10-K filed. |
| 2025-06-12 | Jay Goodman's 6,500 shares of common stock were forfeited and cancelled. |
| 2025-06-17 | Company entered into an Amended and Restated Executive Consulting Agreement with Mr. Jordan and Jordan Consulting. |
| 2025-06-17 | Board adopted the Company's 2025 Option Incentive Plan. |
| 2025-06-17 | Board approved accelerated vesting of 16,000 restricted common shares for Jordan Consulting. |
| 2025-06-17 | Board approved executive option grants to Jordan Consulting for Blair Jordan (41,000 shares) and Eric R. Van Lent (2,500 shares). |
| 2025-06-17 | Board approved executive restricted stock awards to Jordan Consulting for Blair Jordan (16,758 shares) and Eric R. Van Lent (817 shares). |
| 2025-06-17 | Board approved accelerated vesting of 6,500 restricted common shares for Stephen H. Shoemaker, Dr. Lawrence Steinman, and Ryan Smith, and 3,000 for outside legal counsel. |
| 2025-06-17 | Board approved non-executive director option awards to Ryan Smith (25,500 shares), Stephen H. Shoemaker (16,500 shares), and Dr. Lawrence Steinman (11,000 shares). |
| 2025-06-17 | Board approved attorney compensation option award (3,500 shares). |
| 2025-06-17 | Board approved non-executive director restricted stock awards to Ryan Smith (10,218 shares), Stephen H. Shoemaker (6,744 shares), and Dr. Lawrence Steinman (4,496 shares). |
| 2025-06-17 | Board approved attorney compensation restricted stock award (1,839 shares). |
| 2025-06-20 | Shelf registration statement on Form S-3 (File No. 333-288194) initially filed with the SEC. |
| 2025-06-26 | Shelf registration statement declared effective. |
| 2025-07-11 | Board approved accelerated vesting of shares granted on June 17, 2025. |
| 2025-07-12 | First Amendment to Consulting Agreement with Mr. Van Lent and EVL Consulting, LLC, extending the term through December 31, 2025. |
| 2025-07-12 | Board approved accelerated vesting of options granted on June 17, 2025. |
| 2025-07-24 | Stockholders approved an amendment to increase authorized common stock from 100,000,000 to 1,000,000,000 shares. |
| 2025-07-24 | Company filed a Certificate of Amendment to increase authorized common stock, effective immediately. |
| 2025-07-27 | Elray Resources, Inc. exercised all 300,000 Elray Warrants on a cashless basis, resulting in 132,000 common shares issued. |
| 2025-07-28 | Company entered into an amendment to Securities Purchase Agreements (Feb 2021 and Aug 2021) to remove a prohibition on variable rate transactions and reduce warrant exercise price to $26.50. |
| 2025-07-29 | Company entered into a Securities Purchase Agreement (SPA) with accredited institutional investors for a private placement of common stock and pre-funded warrants. |
| 2025-07-29 | Company entered into Strategic Advisor Agreements, granting warrants to purchase 4,557,233 shares of common stock. |
| 2025-07-29 | Board adopted the Company's 2025 Supplemental Option Incentive Plan. |
| 2025-07-29 | Board approved grants of stock options under the 2025 Supplemental Plan to Blair Jordan (390,898 shares), Ryan Smith (390,898 shares), Stephen Shoemaker (91,976 shares), and outside legal counsel (45,988 shares). |
| 2025-08-01 | Company commenced native staking activities. |
| 2025-08-04 | The Private Placement closed. |
| 2025-08-04 | Company entered into an Asset Management Agreement with Electric Treasury Edge, LLC. |
| 2025-08-05 | Dr. Woody's Voting Agreement expired. |
| 2025-08-08 | Company entered into a Securities Purchase Agreement with an institutional investor for $156,250,000 senior secured convertible notes (August 2025 Convertible Notes). |
| 2025-08-08 | August 2025 Note Funding Date. |
| 2025-08-08 | Board approved grants of stock options under the 2025 Second Supplemental Option Incentive Plan to Blair Jordan (77,104 shares), Ryan Smith (77,104 shares), Stephen Shoemaker (18,142 shares), and outside legal counsel (9,077 shares). |
| 2025-08-08 | Board approved the grant of 33,333 restricted stock units (RSUs) to an employee. |
| 2025-08-11 | A holder of warrants to purchase 175 shares of common stock exercised them for cash. |
| 2025-08-11 | A holder of warrants to purchase 10,000 shares of common stock exercised them for cash. |
| 2025-08-12 | Company filed a Certificate of Amendment to change its name to ETHZilla Corporation. |
| 2025-08-13 | Company entered into the Original Sales Agreement with Clear Street LLC to sell shares through an 'at the market' offering. |
| 2025-08-18 | Name Change to ETHZilla Corporation became effective. |
| 2025-08-22 | Board authorized and approved a stock repurchase program for up to $250.0 million of common stock. |
| 2025-08-22 | Company entered into an Amended and Restated Sales Agreement with Clear Street LLC for an 'at the market' offering of up to $10.0 billion. |
| 2025-08-22 | Automatic shelf registration statement on Form S-3 (File No. 333-289811) filed with the SEC. |
| 2025-09-01 | Company commenced liquid staking activities. |
| 2025-09-04 | Blair Jordan and Jordan Consulting entered into a Separation and Release Agreement with the Company. |
| 2025-09-05 | Company entered into an Amended and Restated Asset Management Agreement with Electric Treasury Edge, LLC. |
| 2025-09-08 | Company entered into a collateralized loan agreement with Cumberland DRW LLC for $50,000,000. |
| 2025-09-08 | 180 SPV Treasury Vehicle I LLC entered into a Physically-Settled Spot and Forward Transaction Agreement with Cumberland DRW LLC. |
| 2025-09-15 | Stephen H. Shoemaker resigned as a member of the Board of Directors. |
| 2025-09-15 | Company entered into a consulting agreement with Stephen Shoemaker. |
| 2025-09-15 | Company entered into an Executive Employment Agreement with McAndrew Rudisill, Chief Executive Officer and Executive Chairman. |
| 2025-09-22 | Company entered into an Amendment and Waiver Agreement with the Investor to sell a new series of senior secured convertible notes. |
| 2025-09-22 | Company granted additional warrants (Subsequent Strategic Advisor Warrants) to purchase 907,111 shares of common stock. |
| 2025-09-23 | The new series of senior secured convertible notes (September 2025 Convertible Notes) were sold to the Investor for $360 million. |
| 2025-09-23 | New Debt Funding Date. |
| 2025-09-30 | End of the quarterly period covered by this report. |
| 2025-10-07 | Stockholders approved the issuance of shares of common stock in excess of the August 2025 Exchange Cap. |
| 2025-10-07 | Shareholders voted for the adoption of the 2025 Omnibus Incentive Plan. |
| 2025-10-08 | Stockholders approved an amendment to increase authorized common stock from 1,000,000,000 to 5,000,000,000 shares. |
| 2025-10-08 | Company filed a Certificate of Amendment to increase authorized common stock, effective immediately. |
| 2025-10-14 | Company filed a Certificate of Amendment to effect a 1-for-10 reverse stock split. |
| 2025-10-20 | The 1-for-10 reverse stock split became effective, and common stock began trading on a post-split adjusted basis. |
| 2025-10-22 | Company entered into a Purchase and Subscription Agreement (Satschel Agreement) with Satschel, Inc., acquiring 15% of its fully-diluted capitalization. |
| 2025-10-22 | The acquisition contemplated by the Satschel Agreement closed. |
| 2025-10-28 | Jordan Consulting for Blair Jordan exercised options to purchase 41,000 shares of common stock. |
| 2025-10-29 | Kennedy Trust for Rheumatology Research provided notice of termination of a patent license agreement, effective December 29, 2025. |
| 2025-11-06 | Company's outstanding public warrants expired. |
| 2025-11-06 | Company and CannBioRex Pharma Limited entered into an Assignment and Settlement Agreement (Oxford Assignment Agreement) with Oxford and Oxford University Innovation Limited. |
| 2025-11-11 | Yissum and the Company terminated the Research and License Agreement dated May 13, 2018. |
| 2025-11-12 | Board approved an increase in the annual salary of McAndrew Rudisill, CEO, from $450,000 to $650,000. |
| 2025-11-12 | Board approved an increase in yearly compensation for non-employee directors from $350,000 to $450,000. |
| 2025-11-12 | Company granted 4,816,685 shares of restricted common stock to officers, directors, certain employees, and outside legal counsel. |
| 2025-11-14 | Company entered into an Amended and Restated Sales Agreement with Clear Street LLC and TCBI Securities, Inc. (Texas Capital Securities). |
| 2025-11-15 | John Saunders' appointment as Chief Financial Officer effective. |
| 2025-12-08 | Obligation to repay $51,326,284 for the collateralized loan. |
| 2025-12-29 | Kennedy Trust patent license agreement termination effective. |
| 2025-12-31 | Term of EVL Consulting Agreement extended to this date. |
| 2026-01-02 | Vesting date for half of the 4,816,685 restricted common shares granted on November 12, 2025. |
| 2026-05-08 | Investor has the right to require redemption of the September 2025 Convertible Notes. |
| 2026-06-30 | Stock repurchase program scheduled to expire. |
| 2028-08-08 | Maturity date for the August 2025 Convertible Notes. |
| 2028-09-23 | Maturity date for the September 2025 Convertible Notes. |
| 2028-12-31 | Term of the Rudisill Employment Agreement continues until this date (subject to renewals). |
| 2031-09-30 | Purchase Warrants term expires. |
| 2035-06-17 | Extended expiration date for Stephen Shoemaker's options. |
Recommendation
holdThe company has undergone a radical strategic pivot into the high-growth, yet highly volatile, digital asset and DeFi sector. While the successful capital raises and the alleviation of going concern doubts are positive indicators of financial stability and market confidence in the new direction, the substantial net loss and significant stock-based compensation expenses highlight the early-stage and high-cost nature of this transition. The inherent regulatory and market risks associated with digital assets are considerable. A seasoned investor would likely 'hold' to observe the execution of the new strategy, the company's ability to generate sustainable profits from its digital asset operations, and how it navigates the evolving regulatory landscape, while being mindful of the significant potential for further stock price volatility and dilution.
Keywords
Ethereum, ETH, DeFi, Staking, Digital Assets, Blockchain, Cryptocurrency, Treasury Management, Capital Raise, Convertible Debt, Stock Repurchase, Satschel, Liquidity.io, Tokenization, SEC Filing, Quarterly Report
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.